Forbes Daily: Intel CEO Under Fire After Trump Weighs In

Shares of Eli Lilly plummeted 14% after its experimental obesity drug, orforglipron, showed late-stage trial results for weight loss that fell short of analyst expectations and competitor Novo Nordisk's oral treatment. Meanwhile, OpenAI unveiled its GPT-5 model and is reportedly in talks for a stock sale valuing the AI firm at $500 billion, signaling robust growth in the AI sector. In other market activity, space technology firm Firefly Aerospace saw its IPO surge over 50% on the Nasdaq, and Skydance Media officially closed its $8 billion merger deal with Paramount. Furthermore, Congress rescinded over half of the IRS's Inflation Reduction Act funding, primarily from enforcement, which is projected to significantly reduce government revenues.

Analysis

Significant, event-driven volatility impacted several key stocks, most notably in the biopharmaceutical sector where Eli Lilly (LLY) shares experienced their largest single-day decline since 2000, falling 14%. The drop was a direct reaction to late-stage trial data for its oral obesity drug, orforglipron, which demonstrated a 12% weight loss, falling short of analyst expectations and trailing the 15% efficacy reported by competitor Novo Nordisk (NVO) for its oral treatment. In the technology sector, Intel (INTC) faced politically-driven headwinds, with its stock declining 3% after President Trump called for its CEO's resignation over concerns about ties to Chinese firms, highlighting rising geopolitical risk for the semiconductor giant. In contrast, the market showed strong appetite for new listings in emerging tech, as evidenced by Firefly Aerospace's IPO, which surged over 50% from its $45 offer price. The M&A landscape saw a major resolution with Skydance Media closing its $8 billion merger with Paramount (PARA), ending a period of uncertainty and setting a new strategic direction for the media company. Meanwhile, in the private markets, OpenAI's reported valuation target of $500 billion, a steep increase from its $300 billion valuation in March, signals sustained, powerful investor momentum in the artificial intelligence space.

Key Decisions for Investors

• Re-evaluate positions in the obesity drug market, as Eli Lilly's disappointing trial data materially strengthens the competitive moat for Novo Nordisk's oral treatment.
• Investors in Intel should closely monitor the escalating political and governance risks, as pressure on its leadership could lead to further volatility and strategic uncertainty.
• With the Paramount merger now complete, the investment thesis shifts from M&A arbitrage to execution risk, requiring scrutiny of the new management's ability to deliver on its tech-forward strategy.
• The successful Firefly Aerospace IPO and OpenAI's surging valuation indicate strong investor sentiment for the space and AI sectors, suggesting opportunities in public companies aligned with these secular growth themes.